11 Oct2013
GSK to seek green light for malaria vaccine
British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.
PARIS: British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.
Results for the Phase III stage of the closely-followed RTS, S vaccine were unveiled at a conference in Durban, South Africa, gathering experts on malaria in Africa.
